Sarepta’s only drug may have peaked
Sarepta Therapeutics pulled off a coup in 2016 when it won approval for a rare disease drug despite fervent objections from inside the FDA. Three years later, it looks like that drug has reached its commercial zenith.
Sales of Sarepta’s Exondys 51, approved to treat Duchenne muscular dystrophy, amounted to $87 million in the first quarter. That’s just 3% above what they were the prior quarter, and, when you look at the chart above, Exondys 51 certainly appears to be near its peak.
That’s not altogether surprising. DMD affects about one in 5,000 boys, and Sarepta’s drug is approved only for the roughly 13% of them with a certain genetic mutation. The drug’s sales plateau may have come earlier than some analysts expected, but it was always an inevitability.
And Sarepta has spent the past three years preparing for it. The company has heavily invested in gene therapy and, if all goes according to plan, could string together a series of FDA approvals over the next few years. But if Sarepta’s pipeline falters, it likely won’t be able to count on Exondys 51 for growth.
Sales of Sarepta’s Exondys 51, approved to treat Duchenne muscular dystrophy, amounted to $87 million in the first quarter. That’s just 3% above what they were the prior quarter, and, when you look at the chart above, Exondys 51 certainly appears to be near its peak.
That’s not altogether surprising. DMD affects about one in 5,000 boys, and Sarepta’s drug is approved only for the roughly 13% of them with a certain genetic mutation. The drug’s sales plateau may have come earlier than some analysts expected, but it was always an inevitability.
And Sarepta has spent the past three years preparing for it. The company has heavily invested in gene therapy and, if all goes according to plan, could string together a series of FDA approvals over the next few years. But if Sarepta’s pipeline falters, it likely won’t be able to count on Exondys 51 for growth.
No hay comentarios:
Publicar un comentario